Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations

被引：0

作者：

Gee-Chen Chang

David Chi-Leung Lam

Chun-Ming Tsai

Yuh-Min Chen

Jin-Yuan Shih

Shyam Aggarwal

Shuhang Wang

Sang-We Kim

Young-Chul Kim

Ibrahim Wahid

Rubi Li

Darren Wan-Teck Lim

Virote Sriuranpong

Raymond Tsz-Tong Chan

Robert M. Lorence

Philippe Carriere

Christina Raabe

Agnieszka Cseh

Keunchil Park

机构：

[1] Taichung Veterans General Hospital,Division of Chest Medicine, Department of Internal Medicine

[2] Chung Shan Medical University Hospital,Division of Pulmonary Medicine, Department of Internal Medicine

[3] Chung Shan Medical University,Institute of Medicine and School of Medicine

[4] Queen Mary Hospital,Department of Chest Medicine

[5] The University of Hong Kong,Asan Medical Center

[6] Taipei Veterans General Hospital,Samsung Medical Center

[7] Taipei Veterans General Hospital,undefined

[8] and School of Medicine,undefined

[9] National Yang-Ming Medical University,undefined

[10] National Taiwan University Hospital,undefined

[11] Sir Ganga Ram Hospital Rajinder Nagar,undefined

[12] Beijing Cancer Hospital,undefined

[13] University of Ulsan College of Medicine,undefined

[14] Chonnam National University,undefined

[15] Hwasun Hospital,undefined

[16] Beacon International Specialist Centre,undefined

[17] St Luke’s Medical Center,undefined

[18] National Cancer Centre,undefined

[19] Chulalongkorn University and the King Chulalongkorn Memorial Hospital,undefined

[20] Hong Kong Pacific Centre,undefined

[21] Boehringer Ingelheim Pharmaceuticals,undefined

[22] Inc.,undefined

[23] Boehringer Ingelheim International GmbH,undefined

[24] Boehringer Ingelheim RCV GmBH & Co. KG,undefined

[25] Sungkyunkwan University School of Medicine,undefined

来源：

International Journal of Clinical Oncology | 2021年 / 26卷

关键词：

Afatinib; mutations; Lung cancer; Named patient use; NSCLC; Uncommon ; mutations;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：841 / 850

页数：9

共 50 条

[1] Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
Chang, Gee-Chen
Lam, David Chi-Leung
Tsai, Chun-Ming
Chen, Yuh-Min
Shih, Jin-Yuan
Aggarwal, Shyam
Wang, Shuhang
Kim, Sang-We
Kim, Young-Chul
Wahid, Ibrahim
Li, Rubi
Lim, Darren Wan-Teck
Sriuranpong, Virote
Chan, Raymond Tsz-Tong
Lorence, Robert M.
Carriere, Philippe
Raabe, Christina
Cseh, Agnieszka
Park, Keunchil
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (05) : 841 - 850
[2] Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies
Cappuzzo, Federico
Soo, Ross
Hochmair, Maximilian
Schuler, Martin
Lam, Kwok Chi
Stehle, Gerd
Cseh, Agnieszka
Lorence, Robert M.
Linden, Stephan
Forman, Nicole D.
Hilbe, Wolfgang
Jazieh, Abdul Rahman
Tsai, Chun-Ming
FUTURE ONCOLOGY, 2018, 14 (15) : 1477 - 1486
[3] Named Patient Use Program for Afatinib in Advanced NSCLC with Progression on Prior Therapy: Experience from Asian Centers
Chang, G.
Lam, C. L.
Tsai, C.
Chen, Y.
Shih, J.
Aggarwal, S.
Wang, S.
Kim, S.
Kim, Y.
Wahid, I.
Li, R.
Lim, W.
Sriuranpong, V.
Chan, T. T.
Lorence, R.
Carriere, P.
Raabe, C.
Cseh, A.
Park, K.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S463 - S463
[4] First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea
Kim, Mi-Hyun
Choi, Chang Min
Lee, Sung Yong
Park, Cheol Kyu
Chang, Yoon Soo
Lee, Kye Young
Kim, Seung Joon
Yang, Sei Hoon
Ryu, Jeong Seon
Lee, Jeong Eun
Lee, Shin Yup
Park, Chan Kwon
Lee, Sang Hoon
Jang, Seung Hun
Yoon, Seong Hoon
Jang, Tae Won
ANTICANCER RESEARCH, 2022, 42 (03) : 1615 - 1622
[5] Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study
Moran, Teresa
Taus, Alvaro
Arriola, Edurne
Aguado, Carlos
Domine, Manuel
Gomez Rueda, Ana
Calles, Antonio
Cedres, Susana
Vinolas, Nuria
Isla, Dolores
Palmero, Ramon
Sereno, Maria
Diaz, Victor
Juan, Oscar
Marse, Raquel
Martin Martorell, Paloma
Sanchez Torres, Jose Miguel
CLINICAL LUNG CANCER, 2020, 21 (05) : 428 - +
[6] Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice
Yamada, Yutaka
Tamura, Tomohiro
Yamamoto, Yusuke
Ichimura, Hideo
Hayashihara, Kenji
Saito, Takefumi
Yamada, Hideyasu
Endo, Takeo
Nakamura, Ryota
Inage, Yoshihisa
Satoh, Hiroaki
Iguchi, Kesato
Saito, Kazuto
Inagaki, Masaharu
Kikuchi, Norihiro
Kurishima, Koichi
Ishikawa, Hiroichi
Sakai, Mitsuaki
Kamiyama, Koichi
Shiozawa, Toshihiro
Hizawa, Nobuyuki
Sekine, Ikuo
Sato, Yukio
Funayama, Yasunori
Miyazaki, Kunihiko
Kodama, Takahide
Hayashi, Shigen
Nomura, Akihiro
Nakamura, Hiroyuki
Furukawa, Kinya
Yamashita, Takaaki
Okubo, Hatsumi
Suzuki, Hisashi
Kiyoshima, Moriyuki
Kaburagi, Takayuki
ANTICANCER RESEARCH, 2020, 40 (10) : 5757 - 5764
[7] EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer
de Mello, Ramon Andrade
Madureira, Pedro
Carvalho, Liliana S.
Araujo, Antonio
O'Brien, Mary
Popat, Sanjay
PHARMACOGENOMICS, 2013, 14 (14) : 1765 - 1777
[8] LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both
Katakami, Nobuyuki
Atagi, Shinji
Goto, Koichi
Hida, Toyoaki
Horai, Takeshi
Inoue, Akira
Ichinose, Yukito
Koboyashi, Kunihiko
Takeda, Koji
Kiura, Katsuyuki
Nishio, Kazuto
Seki, Yoko
Ebisawa, Ryuichi
Shahidi, Mehdi
Yamamoto, Nobuyuki
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) : 3335 - +
[9] Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis
Wang, Chunsheng
Zhao, Kewei
Hu, Shanliang
Dong, Wei
Gong, Yan
Xie, Conghua
ONCOLOGIST, 2023, 28 (06) : E397 - E405
[10] Comparison of Afatinib Versus Erlotinib for Advanced Non-Small-Cell Lung Cancer Patients with Resistance to EGFR-TKI
Sakamori, Y.
Yasuda, Y.
Funazo, T.
Nomizo, T.
Tsuji, T.
Yoshida, H.
Nagai, H.
Ozasa, H.
Hirai, T.
Kim, Y. H.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2396 - S2396

← 1 2 3 4 5 →